Comparative Pharmacology
Head-to-head clinical analysis: EMVERM versus NICLOCIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMVERM versus NICLOCIDE.
EMVERM vs NICLOCIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Inhibits oxidative phosphorylation in cestodes, leading to paralysis and death of the parasite.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
2 g orally as a single dose, chewed thoroughly, for taeniasis; may repeat in 1 week for hymenolepiasis.
None Documented
None Documented
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
The terminal elimination half-life of niclosamide is approximately 2-6 hours in patients with normal renal function; however, clinical efficacy against cestodes is prolonged due to its local action in the gastrointestinal tract.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Niclosamide is predominantly excreted in feces as unchanged drug and metabolites after oral administration. Renal excretion of metabolites accounts for less than 2% of an administered dose. Approximately 70% of the dose is recovered in feces within 2-3 days.
Category C
Category C
Anthelmintic
Anthelmintic